Xin Wang

Xin Wang

Auto-generated profile, based on publicly available information

Xin Wang

Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston Texas USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Purpose: CDK6 overexpression is one critical determinant of acquired CDK4/6 inhibitor resistance. Because BRD4 is recruited to the CDK6 promoter, we investigated the potential of bromodomain and extraterminal domain (BET) inhibition to reverse CDK4/6 inhibitor resistance. Experimental Design: Cell viability and survival assays and cell line xenografts were used to evaluate BET inhibition in palbociclib-resistant breast cancer cells. Vehicle- and BET inhibitor–treated cells were subjected to RNA sequencing. CDK6 promoter activity was assessed with luciferase assays, and the miRPathDB version 2.0 database was used to identify potential miRNA mediating the effects of BET inhibition. Experiments were conducted to determine whether continued palbociclib treatment is essential for BET inhibitor efficacy and to explore associated mechanisms. Results: In CDK4/6 inhibitor–resistant models overexpressing CDK6, a cell-cycle gene signature was differentially downregulated following BET inhibition. The BET inhibitors JQ1 and ZEN-3694 reduced the expression of CDK6 and cyclin D1, reinstated CDK4/6 inhibitor–induced cell-cycle arrest, and triggered apoptosis in vitro, as well as tumor regression in vivo. Mechanistically, BET inhibition downregulated CDK6 expression through the induction of miR-34a-5p, rather than by directly repressing the CDK6 promoter. Introduction of a miR-34a-5p inhibitor abrogated BET inhibitor–mediated molecular changes, whereas a miR-34a-5p mimic replicated the effects of BET inhibition. Lastly, resistant cells exhibited downregulation of BCL-2 in the presence of continued palbociclib, associated with reduced estrogen receptor alpha expression, facilitating sensitivity to BET inhibition. Conclusions: Our findings highlight BET inhibition or the application of miR-34a-5p mimics as promising strategies to reverse CDK4/6 inhibitor resistance in a subset of ER+ breast cancers.

15 January 2026 in Journal of Pathology and Translational Medicine
Verified
Journal Article
Open access
EPEundong Park
Eundong Park
MKMichel Kmeid
Michel Kmeid
XWXin Wang
Xin Wang
HQHaiyan Qiu
Haiyan Qiu
CFClifton G Fulmer
Clifton G Fulmer
HLHwajeong Lee
Hwajeong Lee
Background: Prostate-specific membrane antigen (PSMA) is expressed in the neovasculature of various malignancies, such as colorectal cancer (CRC) and hepatocellular carcinoma (HCC). However, PSMA expression in hepatic CRC metastasis has not been studied in detail. Methods: The PSMA expression in primary CRC and corresponding hepatic metastasis was evaluated by immunohistochemistry in a metastatic CRC cohort (n = 56), which was divided into subgroups according to treatment history and timing of metastasis. Demographic and histological characteristics of primary CRC were collected and their relationships with PSMA expression were examined. Additionally, the PSMA expression in resected HCC (n = 76) was compared with that of hepatic CRC metastasis. Results: In primary CRC, PSMA level showed a positive association with tumor size. Lower PSMA expression in hepatic metastasis was associated with higher primary CRC grade, advanced pTNM stage at the time of CRC resection, presence of tumor deposit, and unresectability of metastatic lesion. PSMA expression in primary CRC correlated with that in hepatic metastasis only in concurrent and untreated metastasis subgroup. PSMA expression in primary CRC and hepatic metastasis, regardless of treatment history and timing of metastasis, was not significantly different from that of HCC. Conclusions: Several adverse pathological features of primary CRC were associated with a lower PSMA expression in hepatic metastasis. PSMA expression in hepatic metastasis correlated with that of primary CRC only in concurrent and untreated subgroup. Primary HCC and hepatic CRC metastasis show comparable levels of PSMA expression.

1 April 2025 in AME Case Reports
Verified
Journal Article
Open access
PDF file
XWXin Wang
Xin Wang
NDNoureldien Darwish
Noureldien Darwish
XHXiaoyan Huang
Xiaoyan Huang
Background: Diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (“double-hit” lymphoma) is an uncommon subtype of mature B-cell lymphoma characterized by the concurrent rearrangements of MYC and BCL2 oncogenes. Rarely, aggressive high-grade lymphomas manifest as compartment syndrome, necessitating urgent surgical intervention. Here, we describe a case of high-grade B-cell lymphoma with an unusual presentation of compartment syndrome. Case Description: A 68-year-old woman presented to the emergency room with increased swelling and pain in her right leg, was subsequently diagnosed with right thigh compartment syndrome, and underwent urgent fasciotomy followed by repeat debridement in the medical wound closure. Additionally, the patient was found to have inguinal and external iliac lymphadenopathy along with deep vein thrombosis (DVT). Her past medical history included human immunodeficiency virus (HIV) infection, which was well-controlled with bictegravir, emtricitabine, and tenofovir alafenamide. Excisional biopsy of the right thigh muscle and fluorescence in situ hybridization (FISH) analysis confirmed the diagnosis of high-grade B-cell lymphoma with MYC and BCL2 gene rearrangements arising in the setting of immunodeficiency/dysregulation (lymphoma associated with HIV infection). Despite aggressive medical management in the intensive care unit, the patient succumbed to the disease and ultimately died from sepsis and hemorrhagic shock. Conclusions: High-grade B-cell lymphoma with MYC and BCL2 rearrangements represents an aggressive lymphoma with a poor prognosis. The unusual manifestation of this lymphoma involving skeletal muscle and presenting as compartment syndrome is rare. Unfortunately, the patient passed away shortly after undergoing debridement surgery. This case highlights the importance for clinicians to be vigilant and attentive to atypical presentations, as delays in diagnosis and treatment can have significant consequences. Early recognition and prompt intervention are crucial in saving the patient’s life.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Synergy analyses of the effects of the combination of palbociclib and JQ1.

1 December 2025
Verified
Other
Open access
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Purpose:CDK6 overexpression is one critical determinant of acquired CDK4/6 inhibitor resistance. Because BRD4 is recruited to the CDK6 promoter, we investigated the potential of bromodomain and extraterminal domain (BET) inhibition to reverse CDK4/6 inhibitor resistance.Experimental Design:Cell viability and survival assays and cell line xenografts were used to evaluate BET inhibition in palbociclib-resistant breast cancer cells. Vehicle- and BET inhibitor–treated cells were subjected to RNA sequencing. CDK6 promoter activity was assessed with luciferase assays, and the miRPathDB version 2.0 database was used to identify potential miRNA mediating the effects of BET inhibition. Experiments were conducted to determine whether continued palbociclib treatment is essential for BET inhibitor efficacy and to explore associated mechanisms.Results:In CDK4/6 inhibitor–resistant models overexpressing CDK6, a cell-cycle gene signature was differentially downregulated following BET inhibition. The BET inhibitors JQ1 and ZEN-3694 reduced the expression of CDK6 and cyclin D1, reinstated CDK4/6 inhibitor–induced cell-cycle arrest, and triggered apoptosis in vitro, as well as tumor regression in vivo. Mechanistically, BET inhibition downregulated CDK6 expression through the induction of miR-34a-5p, rather than by directly repressing the CDK6 promoter. Introduction of a miR-34a-5p inhibitor abrogated BET inhibitor–mediated molecular changes, whereas a miR-34a-5p mimic replicated the effects of BET inhibition. Lastly, resistant cells exhibited downregulation of BCL-2 in the presence of continued palbociclib, associated with reduced estrogen receptor alpha expression, facilitating sensitivity to BET inhibition.Conclusions:Our findings highlight BET inhibition or the application of miR-34a-5p mimics as promising strategies to reverse CDK4/6 inhibitor resistance in a subset of ER+ breast cancers.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
RNA-seq analysis in vehicle and JQ1-treated palbociclib-resistant MCF7-R100 cells.